|
Feb 24
|
Teva and Alvotech launch ustekinumab biosimilar injection in US
|
|
Feb 24
|
Sanofi and Teva report new outcomes from Phase IIb trial of duvakitug
|
|
Feb 22
|
Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease
|
|
Feb 21
|
Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
|
|
Feb 20
|
Billionaire Stanley Druckenmiller Dumped Duquesne's Entire Stake in Broadcom and Bought One of Wall Street's Hottest Drug Stocks Hand Over Fist
|
|
Feb 19
|
Is Teva Pharmaceutical (TEVA) Trading at a Discount?
|
|
Feb 18
|
Teva to Host Conference Call on February 24, 2025 to Discuss New Data Presented for Duvakitug (anti-TL1A) Positive Phase 2b results at the 20th Annual Congress of the European Crohn's and Colitis Organisation (ECCO)
|
|
Feb 18
|
FDA To Review Teva and Alvotech Drug That Could Compete With Regeneron's Eylea
|
|
Feb 18
|
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)
|